[{"data":1,"prerenderedAt":25},["ShallowReactive",2],{"project-41d75f4069ef5fe500d7ee1c324c3feb":3},{"_id":4,"slug":4,"title":5,"subtitle":6,"cover":8,"tech_type":9,"indications":10,"official_price":11,"hospital_name":12,"hospital_names":13,"tech_company_name":12,"view_count":14,"favorite_count":15,"is_favorite":16,"approval_no":17,"approval_date":9,"regulatory_level":18,"valid_until":9,"filing_date":19,"intro":20,"detail_desc":21,"target_population":22,"compliance_list":23,"process":24},"41d75f4069ef5fe500d7ee1c324c3feb","预防肝癌术后复发的活化 T 淋巴细胞应用技术",[7],"肝癌","https://6875-huali-cell-8geyb3yje6a285d1-1419749029.tcb.qcloud.la/assets/covers/cover-02.jpg","",[7],"10万/次","北京永泰生物制品有限公司",[],80,1,false,"乐城第四批获批","低风险","2025年","\u003Cp>自体活化 T 淋巴细胞回输,辅助根治性肝癌术后患者降低复发风险。\u003C/p>\u003Cp>\u003Cb>适应症\u003C/b>:肝癌术后辅助 / 预防复发\u003Cbr/>\u003Cb>技术类型\u003C/b>:前沿医疗\u003Cbr/>\u003Cb>批次\u003C/b>:乐城第四批获批\u003C/p>","自体活化 T 淋巴细胞回输,辅助根治性肝癌术后患者降低复发风险。",[],[],[],1779368115444]